[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617

SIMPLE SUMMARY: Prostate-specific membrane antigen (PSMA) radioligands have proven effective to treat patients with metastatic castration-resistant prostate cancer. Targeted α-therapy using actinium-225 has been used for patients with end-stage disease who no longer responded to β(ࢤ)-therapy through...

Descripción completa

Detalles Bibliográficos
Autores principales: Busslinger, Sarah D., Tschan, Viviane J., Richard, Olivia K., Talip, Zeynep, Schibli, Roger, Müller, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688344/
https://www.ncbi.nlm.nih.gov/pubmed/36428743
http://dx.doi.org/10.3390/cancers14225651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688344/
https://www.ncbi.nlm.nih.gov/pubmed/36428743
http://dx.doi.org/10.3390/cancers14225651

Ejemplares similares